Skip to content
Study details
Enrolling now

Bipolar Androgen Therapy for Prostate Cancer

Roswell Park Cancer Institute
NCT IDNCT06305598ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

14

Study length

about 3 years

Ages

18+

Sex

Male only

Locations

1 site in NY

What this study is about

This trial is testing a new treatment called bipolar androgen therapy, which involves regulating testosterone levels in men with advanced prostate cancer that has spread. The goal of this treatment is to see if it can change how sensitive the cancer cells are to hormone therapies and improve side effects.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Survey Administration
  • 2.Take Leuprolide Acetate
  • 3.Take Testosterone Cypionate
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVintramuscular

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Antineoplastic Agent [TC] (Gonadotropin Releasing Hormone Receptor Agonists), Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) (Androgen Receptor Agonists)

Drug routes

injection, intramuscular

Endpoints

Secondary: Assess Fatigue, Assess Quality of Life, Assess change in Fatigue, Incidence of adverse events, Incidence of serious adverse events, Overall survival, Progression free survival

Procedures

biopsy, imaging

Body systems

Oncology